GO
Loading...

Amgen Inc

More

  • US STOCKS-Biotech shares drop, Amarin plunges 20 pct Friday, 12 Sep 2014 | 12:49 PM ET

    NEW YORK, Sept 12- Biotech stocks were among the weakest sectors on Friday, falling as investors continued to take profit in the high-flying sector. Vertex Pharmaceuticals lost 1.2 percent to $93.10 while Amgen was off 0.9 percent to $137.64 and Regeneron Pharma lost 1 percent to $346.82.

  • Early Glance: Biotechnology companies Friday, 12 Sep 2014 | 11:13 AM ET

    Amgen Inc. fell$. 59 or. 4 percent, to $138.38. Biogen Idec fell $2.52 or. 8 percent, to $324.59. Celgene Corp. fell$. 13 or. 1 percent, to $91.83.

  • Final Glance: Biotechnology companies Thursday, 11 Sep 2014 | 6:02 PM ET

    Amgen Inc. fell$. 23 or. 2 percent, to $138.96. Biogen Idec fell $4.97 or 1.5 percent, to $327.11. Celgene Corp. fell $2.13 or 2.3 percent, to $91.96.

  • Midday Glance: Biotechnology companies Thursday, 11 Sep 2014 | 2:09 PM ET

    Amgen Inc. fell$. 83 or. 6 percent, to $138.36. Biogen Idec fell $6.31 or 1.9 percent, to $325.77. Celgene Corp. fell $2.51 or 2.7 percent, to $91.58.

  • Early Glance: Biotechnology companies Thursday, 11 Sep 2014 | 10:29 AM ET

    Amgen Inc. rose$. 03 or percent, to $139.22. Biogen Idec fell $1.85 or. 6 percent, to $330.23. Celgene Corp. fell$. 88 or. 9 percent, to $93.21.

  • Final Glance: Biotechnology companies Wednesday, 10 Sep 2014 | 6:16 PM ET

    Amgen Inc. rose $1.80 or 1.3 percent, to $139.19. Biogen Idec rose $5.25 or 1.6 percent, to $332.08. Celgene Corp. rose $1.16 or 1.2 percent, to $94.09.

  • Midday Glance: Biotechnology companies Wednesday, 10 Sep 2014 | 1:21 PM ET

    Amgen Inc. rose $1.34 or 1.0 percent, to $138.73. Biogen Idec rose $5.43 or 1.7 percent, to $332.26. Celgene Corp. rose$. 98 or 1.1 percent, to $93.91.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.

  • US STOCKS-Futures point to flat open after recent rally Thursday, 14 Aug 2014 | 8:54 AM ET

    *Cisco down in premarket after results, outlook. NEW YORK, Aug 14- U.S. stock index futures pointed to a flat open on Thursday as investors found few reasons to buy following a sharp rally in the previous session and amid signs of weakness in Europe and ongoing uncertainty over Ukraine.

  • Yaron Werber, Citi Investment Research, shares his thoughts on news Kyprolis failed to meet its primary endpoint of improving overall survival for patients with multiple myeloma.

  • Early movers: WMT, KSS, GE, UPS, AMGN, GMCR & more Thursday, 14 Aug 2014 | 7:40 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Aug 13- Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. Shares of Amgen were down 2.1 percent at $124.66 in after-hours trading on Wednesday.

  • After-hours buzz: Cisco, NetApp, Amgen and more Wednesday, 13 Aug 2014 | 5:04 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Wednesday's after-hours movers: Cisco, NetApp, Amgen and more

  • Aug 13- A Phase 3 trial of Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. Shares of Amgen were down 2.3 percent at $124.41 in after-hours trading on Wednesday.